You are here: Industry Insights > Novavax

News List

Novavax plans FDA filing after NanoFlu trumps Sanofi flu vaccine pharmatimes
March 27, 2020
Novavax has unveiled new Phase III data showing that its recombinant quadrivalent seasonal influenza vaccine candidate, NanoFlu, met all primary endpoints in adults aged 65 and older against Sanofi’s Fluzone Quadrivalent.
Novavax’s Nanoflu compares well to Fluzone Quadrivalent pharmaceutical-technology
March 26, 2020
US-based Novavax has published top-line Phase III data for its seasonal influenza vaccine Nanoflu in adults aged 65 and over.
Novavax secures CEPI funding for Covid-19 vaccine pharmaceutical-technology
March 12, 2020
Novavax has received initial funding of $4m from the Coalition for Epidemic Preparedness Innovations (CEPI) for the development of a Covid-19 vaccine.
Emergent BioSolutions, Novavax Enter COVID-19 Pact contractpharma
March 11, 2020
Emergent BioSolutions has entered into a COVID-19 agreement with Novavax. It will collaborate with Novavax, utilizing its molecule-to-market contract development and manufacturing (CDMO) services to support bringing ...
Novavax starts animal testing of coronavirus vaccine candidates pharmaceutical-technology
March 03, 2020
US-based biotechnology company Novavax has begun testing its new coronavirus vaccine candidates in animal models.
Novavax Advances Development of COVID-19 Vaccine contractpharma
March 03, 2020
Novavax, Inc., a late-stage biotechnology company developing next-gen vaccines for serious infectious diseases, has advanced its efforts to develop a novel vaccine to protect against coronavirus disease COVID-19.
Catalent snaps up Novavax production sites and 100 employees in $18M deal fiercepharma
July 04, 2019
Another deal has been struck in the rapidly evolving market for gene therapy manufacturing. Just two months after Catalent jumped big time into the gene therapy realm, it is adding a couple of small vaccine production sites and a 100 employees to its oper
Novavax details 'pre-commercialization activities,' $1.5B sales target for RSV vaccine fiercepharma
March 22, 2018
Novavax may be years away from a potential approval of its RSV vaccine

Previous page 1 2 3 4 5 6 7 8 9 10 ... 14 15 Next page